| Company Name: | Aastrom Biosciences, Incorporated | | Ticker Symbol: | ASTM | | | WWW Address: | www.aastrom.com | | CEO: | George W. Dunbar, Jr. | | No. of Employees: | 48 | | Common Issue Type: | CS | | Business Description: | The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.31 |  0.0 | 0.29 | 0.52 | 0.3134 | 0.31 | 0.30 | 710034 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 53.9 | 174.0 | -0.47 | -0.11 | 0.00 | 0.0 | 0.0 | 0.78 - 0.29 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.31 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 53.9 | mil |
| Latest Shares Outstanding | 174.0 | mil |
| Earnings pS (EPS) | -0.11 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 3,792 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 168.0 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 2,008.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 5,032.50 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -78.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -87.6 | % |
| Current Ratio | 9.0 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.04 | |
| LT Debt/Total Capital | 1.0 | % |
| Working Capital pS | 0.10 | $ |
| Cash pS | 0.10 | $ |
| Book-Value pS | 0.10 | $ |
| Tangible Book-Value pS | 0.10 | $ |
| Cash Flow pS | -0.09 | $ |
| Free Cash Flow pS | -0.08 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.02 | |
| Price/Tangible Book Ratio | 3.02 | |
| Price/Cash Flow | -3.6 | |
| Price/Free Cash Flow | -3.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -8.8 | 91 | 13,211 | 48,088 |
| 4 Weeks | 0.37 | 0.29 | 0.34 | -8.8 | 90 | 12,134 | 242,686 |
| 13 Weeks | 0.52 | 0.29 | 0.45 | -31.1 | 65 | 16,253 | 1,040,213 |
| 26 Weeks | 0.59 | 0.29 | 0.36 | -13.9 | 70 | 15,660 | 1,988,864 |
| 52 Weeks | 0.78 | 0.29 | 0.35 | -11.4 | 65 | 16,147 | 4,052,955 |
| YTD | 0.78 | 0.29 | - | -38.0 | 51 | 17,182 | 3,865,921 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.31 | 0.32 | 0.37 | 0.39 | 0.39 | -0.47 | -0.51 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -27.62 | 83.0 | -35.55 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -25.31 | NA | -66.53 |
| R&D | 14.46 | NA | 5.41 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 170.4 | 170.4 | -65.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.01 | 0.01 | 0.05 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 83.54 |
| Current Ratio | 10.5 |
| Quick Ratio (Acid Test) | 10.1 |
| Liquidity Ratio (Cash) | 10.08 |
| Receivables Turnover | 4.8 |
| Average Collection Period | 75 |
| Working Capital/Equity | 93.2 |
| Working Capital pS | 0.10 |
| Cash-Flow pS | -0.10 |
| Free Cash-Flow pS | -0.09 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 13.37 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 10.3 |
| Total Debt/Equity (Gearing Ratio) | 0.05 |
| LT Debt/Equity | 0.02 |
| LT Debt/Capital Invested | 1.7 |
| LT Debt/Total Liabilities | 15.3 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.42 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.32 |
| Tobin's Q Ratio | 2.80 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.51 |
| Enterprise Value (EV)/Free Cash Flow | -2.68 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.02 |
| Price/Book Ratio - LTM | 3.02 |
| Price/Cash Flow Ratio | -3.6 |
| Price/Free Cash Flow Ratio - LTM | -3.9 |
| Price/Sales Ratio | 236.54 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.01 |
| Tangible Book Value pS - LTM | 0.10 |
| Book Value pS - LTM | 0.10 |
| Capital Invested pS | 0.10 |
| Cash pS - LTM | 0.10 |
| Cash Flow pS - LTM | -0.09 |
| Free Cash Flow pS - LTM | -0.08 |
| Earnings pS (EPS) | -0.11 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -7,604.40 |
| Free Cash Flow Margin 5YEAR AVG | -3,329.13 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.01 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.01 |
| Return on Capital Invested (ROCI) | -90.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -56.0 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -82.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | -52.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 115 |
| Revenue per Employee | 3,792 |
| Net Income per Employee | -332,208 |
| Average Collection Period | 115 |
| Receivables Turnover | 4.8 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | -1124.0 |
| Inventory/Sales | 0.5 |
| Accounts Payble/Sales | 468.68 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.01 |
| Fixed Assets Turnover | 0.12 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.01 |
| Revenue per $ Plant | 0.12 |
| Revenue per $ Common Equity | 0.01 |
| Revenue per $ Capital Invested | 0.01 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 2719.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1111.7 |
| Research & Devlopment (R&D) as % of Revenue | 6202.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 6202.7 |
|
|  
| | |  |  | |
| |